Research has confirmed that congestive heart failure is significantly more common in people given an anthracycline to treat breast cancer or lymphoma than among those given other types of chemotherapy, even after adjusting for confounding factors.

DOI [Teaser] Key Points Spontaneous reporting systems are needed to detect and better characterize adverse events (AEs) with anaplastic lymphoma kinase (ALK) inhibitors in a timely manner in the real world.

Cutaneous T-cell lymphomas are a heterogeneous group of T-lymphocyte malignancies with currently only one potentially curative treatment option, which has limited applicability. Dawn Queen, Adriana Lopez, and Larisa Geskin (Columbia University Medical Center, USA) explore the most promising emerging treatment options. 

The average age of cancer diagnosis was 31.5 years and the most common tumor type in the cohort was breast cancer, in 17.2%, followed by lymphoma, thyroid cancer, and melanoma, in a respective 14.8%, 12.6%, and 11.0%.

Patients with follicular lymphoma who achieve a positron emission tomography-determined complete response to induction immunochemotherapy have a significantly better prognosis than those with a non-complete response, research shows.

And indeed, mogamulizumab was recently approved by the US FDA for the treatment of these cutaneous T-cell lymphoma subtypes.

The FDA has expanded the indication for brentuximab vedotin to include patients with systemic anaplastic large cell lymphoma and other forms of peripheral T-cell lymphoma that express CD30 who are undergoing CHOP chemotherapy.

Phase III trial data have highlighted the value of antimüllerian hormone as a biomarker of ovarian toxicity associated with different chemotherapy regimens for advanced Hodgkin lymphoma.

The birth rate for women who are relapse-free after treatment for Hodgkin lymphoma has risen in recent years, becoming comparable with that of the general population regardless of disease stage or treatment.

Treatment-naïve follicular lymphoma patients have similar outcomes regardless of whether they receive lenalidomide or chemotherapy in combination with rituximab, suggest phase III trial findings published in The New England Journal of Medicine .

The 2-year follow-up results from the phase I/II ZUMA-1 trial of patients with refractory large B-cell lymphoma show that the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel remains efficacious and manageable in the long term.

This program was made possible thanks to independent educational sponsorship from MorphoSys.

Cutaneous T-cell lymphomas are a heterogeneous group of T-lymphocyte malignancies with only one potentially curative treatment option that has limited applicability. Dawn Queen, Adriana Lopez, and Larisa Geskin (Columbia University Medical Center, USA) explore the most promising emerging alternative treatment options. 

US researchers have detailed the pathophysiology, clinical presentation, and management of breast implant-associated anaplastic large cell lymphoma in a move to educate healthcare professionals dealing with this rare but increasingly common diagnosis.

With regard to efficacy, the highest ORRs were observed among participants with nonmelanoma skin cancer, Hodgkin’s lymphoma, or Kaposi’s sarcoma, at 69%, 67%, and 60%, respectively, followed by rates of 47% among those with melanoma and 31% among those with NSCLC.

medwireNews : The US FDA has given approval for the use of the antibody–drug conjugate brentuximab vedotin in patients undergoing chemotherapy for treatment-naïve stage III or IV classical Hodgkin lymphoma.

Ibrutinib plus venetoclax could together be beneficial as oral treatment for mantle-cell lymphoma, suggests a phase II study published in The New England Journal of Medicine .

Treatment with obinutuzumab-based chemotherapy prolongs progression-free survival over rituximab-based therapy in patients with follicular lymphoma, GALLIUM trial data suggest.

Silicone-filled breast implants are associated with a high relative risk for developing anaplastic large-cell lymphoma in the breast, but the absolute risk remains low, confirms a population-based study.